5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns over certain operational trends. Management credited the quarter’s results to continued strength in core product lines—especially Artegraft, which saw exceptional international growth—and disciplined pricing strategies. CEO George LeMaitre noted, “Worldwide Artegraft sales grew 36% in Q1,” while also acknowledging product and geographic expansion as central to recent performance. Looking ahead, LeMaitre’s guidance is built on continued international rollout of Artegraft, further pricing initiatives, and operational investments to support expansion. Management highlighted upcoming launches in Canada and other regions, new product variants, and ongoing salesforce growth as key contributors to expected growth. CFO Dorian LeBlanc stated, “We are increasing our annual guidance for gross margin to 72.3%,” emphasizing the company’s focus on margin improvement and direct-to-hospital sales execution. LeMaitre (LMAT) Q1 CY2026 Highlights: Revenue: $66.55 million vs analyst estimates of $66.72 million (11.2% year-on-year growth, in line) EPS (GAAP): $0.68 vs analyst estimates of $0.66 (3% beat) Adjusted EBITDA: $22.36 million vs analyst estimates of $20.19 million (33.6% margin, 10.8% beat) The company reconfirmed its revenue guidance for the full year of $280 million at the midpoint EPS (GAAP) guidance for the full year is $3.01 at the midpoint, beating analyst estimates by 3.5% Operating Margin: 26.7%, up from 21.1% in the same quarter last year Organic Revenue rose 10% year on year (miss) Market Capitalization: $2.32 billion While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From LeMaitre’s Q1 Earnings Call